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Editorial
The Irish pharmaceutical industry continues to 
be an international success story and this article 
outlines the achievements of the industry and 
discusses the main threats and opportunities 
for future development. The sector took off in 
the 1970s following the Industrial Development 
Authority’s adoption of pharmaceuticals as one 
of its target sectors. This resulted in a series of 
manufacturing investments, notably by US- and 
UK-based companies. Currently, Ireland’s main 
strengths in attracting foreign investment in 
pharmaceuticals include its low rate of corpora-
tion tax (12.5%), its educated labor force, access 
to the European market, well-developed regu-
latory capabilities and a supportive industrial 
development agency.
Since its inception, the pharmaceutical sector 
in Ireland has experienced strong and nearly 
continuous employment growth. In 1998, the 
sector already accounted for approximately 
20,000 jobs (pharmaceutical sector is here defined 
as NACE 21) [101]. Employment continued 
to grow to approximately 30,000 in 2007. 
However, numbers fell slightly at the start of 
the global economic crisis in 2008. Remarkably, 
employment picked up strongly again, reaching 
a historic height of 31,000 in 2010, after which 
numbers again dropped a little in 2011. The 
growth of employment in the Irish pharmaceutical 
industry, even at a time when employment in 
other manufacturing industries started to decline, 
has significantly increased its relative importance. 
The share of the pharmaceutical industry in total 
manufacturing employment has increased from 
under 6.9% in 1998 to 14.8% in 2011. 
The sector’s performance in terms of external 
trade is even more impressive. Exports grew 
from €24.6 billion in 2000 to €51.8 billion in 
2011 (pharmaceutical sector is here defined as 
to include organic chemicals, pharmaceutical 
preparations and essential oils) [101]. Even during 
the economic crisis, exports grew continuously. 
Given the less positive performance of other 
merchandise sectors, the pharmaceutical sector 
has now become the dominant exporting sector, 
accounting for 56% of Irish merchandise exports 
in 2011.
The strong export performance is, to an 
extent, ref lected in Ireland’s position as a 
global pharmaceutical exporting nation. UN 
Comtrade data show that the shares of global 
pharmaceutical exports recorded for most 
traditional pharmaceutical exporting countries, 
such as the UK, Germany and the USA, 
have all substantially shrunk since the mid-
1980s. In contrast, Ireland’s market share in 
pharmaceuticals has grown substantially, from 
1.9% in 1985 to 7.8% in 2005, after which it 
fell slightly to 7.2% in 2010. By 2010 Ireland 
was the fifth-largest exporter of pharmaceuticals 
in the world. The recent slight fall in Ireland’s 
share, in spite of the strong export growth 
figures, is partly explained by the emergence of 
new pharmaceutical exporting nations, notably 
China. The Chinese pharmaceutical industry 
has experienced very strong growth as absolute 
exports increased more than sixfold between 
2000 and 2010.  
Aside from these achievements, a number of 
weaknesses are evident. The Irish pharmaceutical 
industry remains strongly manufacturing 
focused. Although many manufacturing 
subsidiaries have established process R&D 
capability, multinational corporations have 
invested very little in discovery and clinical 
trials research. Attracting internationally 
mobile discovery units was not considered a 
realistic option because, until recently, the 
relevant science and technology infrastructure 
was poor by international standards. This has 
changed profoundly since 2000, when the Irish 
Government established a major science and 
technology funding program in the form of the 
Science Foundation Ireland.
Another weakness is the fact that Ireland’s 
pharmaceutical industry remains largely 
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dependent on foreign direct investment. In 2003, 
subsidiaries of foreign companies accounted for 
93% of employment in (manufacturing active) 
pharmaceutical companies [1]. The Science 
Foundation Ireland funding has stimulated a 
growing body of Irish scientists and an increase 
in indigenous start-up companies. However, the 
number of start-ups that have brought products 
to the clinical trial stage is, as yet, relatively 
small [2].
Notwithstanding these weaknesses, the Irish 
pharmaceutical industry should be considered 
a success. However, while the industry’s 55% 
share of Irish merchandise exports is impressive, 
it leaves Ireland vulnerable to changes in the 
external environment. There are two main 
threats to the further growth and development 
of the industry: the patent cliff and the incipient 
offshoring of pharmaceutical activities.
In 2011, the pharmaceutical industry 
reached the edge of the patent cliff. A large 
number of major blockbusters are coming off 
patent in 2011 and 2012. At least six of the top 
ten global drugs coming off patent are currently 
produced in Ireland. Global Pharmaceutical 
Market Review data suggest that prior to patent 
expiry, these six drugs alone represented global 
revenues of US$40 billion. As soon as these 
drugs come off patent, their value will be 
significantly reduced – in some cases literally 
decimated. Not all the production involved is 
undertaken in Ireland, but a substantial portion 
is. The patent cliff will, therefore, have a strong 
impact on Irish exports. 
The precise impact partly depends on several 
strategic decisions on the side of the originator 
and generic companies. After expiry, the 
originator companies may or may not decide 
to continue production of the drug. They may 
choose to continue production in Ireland or 
move offshore. Equally, generic competition may 
choose to produce the drug in Ireland or, more 
likely, elsewhere. But whoever ends up producing 
the drug and wherever it is produced, the value 
will be significantly reduced – by billions of 
Euros. As further products come off patent, this 
issue will continue to haunt Ireland after 2012.
Although the blockbuster drugs coming off 
patent account for an important share of Irish 
pharmaceutical exports, they are produced by a 
relatively small proportion of the pharmaceutical 
workforce. The direct impact on employment 
and the future development of the industry 
will, therefore, be relatively limited. Indeed, it 
may be the incipient outsourcing and offshoring 
activities by pharmaceutical companies that pose 
the greater threat.
In the context of reduced rates of revenue 
growth and increasing costs, an increasing 
number of companies have begun to outsource 
noncore activities. Some companies have started 
to outsource the early stages of the active 
ingredient synthesis cycle. Moving back into the 
synthesis chain, the regulatory requirements tend 
to be lower and, as a result, skill requirements 
and the level of regulation diminish. Partly 
due to Ireland’s rapidly rising wage levels of 
the Celtic Tiger era, very few processes are 
outsourced to companies in Ireland. Over the 
last decade, the pharmaceutical companies 
have increasingly used low-cost suppliers in 
India and China, mainly for lower value-added 
supplies. Most pharmaceutical companies 
remain reluctant to offshore/outsource the 
later-stage synthesis to companies in India and 
China, doubting whether these countries have 
the requisite technical knowledge and can meet 
the standards required to supply the highly 
regulated markets. This perception is changing, 
however, and pharmaceutical companies have 
even begun to contemplate setting up their own 
active ingredient plants in China and India [1].
In the face of a reduction in the number of 
blockbusters coming out of the development 
pipelines and increased competition from 
other countries as locations for pharmaceutical 
production, subsidiaries in Ireland have 
identified opportunities to reposition themselves 
in the global production networks of their parent 
companies. Most subsidiaries are developing 
into strategic launch plants and flexible multi-
product plants, capable of producing the high 
value-added stages of the chemical synthesis 
chain as well as the smaller volume, high-value, 
niche products. Building a core capability in 
these more regulated and skill-intensive activities 
is one opportunity to cement the chemical 
pharmaceutical industry in Ireland.
Additional opportunities lie in the area of 
process R&D. Driven by a search for greater 
efficiencies in the process R&D development 
chain, pharmaceutica l companies are 
increasingly co-locating process R&D functions 
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with their main overseas manufacturing 
operations [3]. Apart from providing new jobs, 
the establishment of such activities will lead to 
significant skill upgrading. A survey of Irish 
pharmaceutical companies has shown that 
between 2001 and 2006 the number of staff 
involved in process R&D almost doubled, from 
408 to 800. A total of 30% of the employees 
involved hold a PhD degree [4]. 
Probably the greatest hope for the 
development of the pharmaceutical industry 
lies in biopharmaceuticals. Since 2000, Ireland 
has been emerging as an increasingly important 
location for biopharmaceutical fermentation 
plants. Ireland now has over ten large-scale 
biopharmaceutical facilities. During the last 
year alone six blue-chip companies invested in 
biopharmaceutical facilities, announcing over 
850 jobs. The rise of biotechnology, besides 
providing additional jobs, has the potential 
to change Ireland’s relative role in global 
manufacturing networks. Compared with 
chemical pharmaceuticals, biopharmaceutical 
production requires even more highly skilled 
staff and a greater process R&D effort. In most 
cases, the Irish facility is one of only one or two 
facilities outside a company’s home country, 
making it a strategic facility supplying global 
markets from the beginning.
In conclusion, the Irish pharmaceutical 
industry is in a healthy state. The patent cliff 
will mainly affect exports and will have a more 
limited effect on employment. The threat of 
offshoring of chemical synthesis activities will 
at least be partially offset by new investments 
in biopharmaceuticals. The main challenges 
for the medium term will be to diversify from 
manufacturing-oriented activities to higher 
value-added R&D functions and a greater 
involvement of indigenous actors and resources. 
The presence of a manufacturing-oriented cluster 
is only of limited benefit in this regard. Discovery 
functions require different skill sets that are, as 
yet, in short supply in Ireland [1]. Diversification 
into discovery will basically require the 
development of a separate research-based cluster. 
The recent Science Foundation Ireland funding 
is unlikely to attract the large-scale discovery 
units of the global drug companies, not even 
in the medium term. The more realistic route 
will involve the slower process of developing an 
indigenous capacity, in the form of university 
spin-outs and private sector spin-offs. 
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